The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXXVI.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

Publications

Li L, Wang Z, Cui L, Xu Y, Guan K, Zhao B

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.

Clinical and translational allergy. 2021;11(4):e12038

Jingo K, Harada N, Nishioki T, Torasawa M, Yamada T, Asao T, Takagi H, Takeshige T, Ito J, Takahashi K

Anaphylaxis to three humanized antibodies for severe asthma: a case study.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2020;16:46

Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T, Schwartz L

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.

The Journal of allergy and clinical immunology. 2011;128(1):210-2

Kim HL, Leigh R, Becker A

Omalizumab: Practical considerations regarding the risk of anaphylaxis.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2010;6(1):32

Lin RY, Rodriguez-Baez G, Bhargave GA

Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2009;103(5):442-5

Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.

Respiratory medicine. 2009;103(8):1098-113

Limb SL, Starke PR, Lee CE, Chowdhury BA

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.

The Journal of allergy and clinical immunology. 2007;120(6):1378-81

Chipps B

Systemic reaction to omalizumab.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2006;97(2):267

Dreyfus DH, Randolph CC

Characterization of an anaphylactoid reaction to omalizumab.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2006;96(4):624-7